Patent Assignment
Reel/Frame 060616/0923
Security Interest
Recorded: 2022-07-08
Pages: 21
Assignor
BLUEPRINT MEDICINES CORPORATION
Executed: 2022-06-30
Assignee
TAO TALENTS, LLC
2100 MCKINNEY AVE, SUITE 1500, DALLAS, TEXAS, 75201
Covered Properties
(107)
MAP4K1 Inhibitors
MAP4K1 Inhibitors
Application:
63/221,710 →
MAP4K1 Inhibitors
Application:
63/221,825 →
MAP4K1 Inhibitors
Application:
63/222,341 →
Egfr Inhibitors
Egfr Inhibitors
Application:
63/327,631 →
Kit Inhibitors
Application:
63/332,387 →
NTRK2 Fusions
Application:
16/529,244 →
Publication:
US 2019/0389969
Met Fusions
Application:
15/304,637 →
Publication:
US 2017/0044621
RAF1 Fusions
Application:
17/490,712 →
Publication:
US 2022/0205045
Prkc Fusions
Application:
17/581,669 →
Publication:
US 2022/0213553
Prkacb Fusions
Application:
15/526,896 →
Publication:
US 2017/0356052
Inhibitors of the Fibroblast Growth Factor Receptor
Application:
17/102,628 →
Publication:
US 2021/0347756
Inhibitors of the Fibroblast Growth Factor Receptor 4 in Combination with Cyclin-Dependent Kinase Inhibitors
Application:
16/331,341 →
Publication:
US 2019/0192522
Inhibitors of Ret
Application:
17/669,785 →
Publication:
US 2022/0315560
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Treatment of Egfr-Mutant Cancer
Application:
17/267,149 →
Publication:
US 2021/0308134
CDK2 Inhibitors
CDK2 Inhibitors
Application:
63/327,474 →
CDK2 Inhibitors and Methods of Making and Using Same
Application:
63/281,508 →
Fused Pyrimidine Compounds, Compositions and Medicinal Applications Thereof
Application:
17/764,092 →
Publication:
US 2023/0027026
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application:
63/236,194 →
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application:
63/271,991 →
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application:
63/271,993 →
Egfr Inhibitors for Treatment of Cancer
Application:
63/322,371 →
Salt and Crystal Forms of an Epidermal Growth Factor Receptor Inhibitor
Application:
63/338,371 →
Inhibitors of Activin Receptor-Like Kinase
Salt and Crystal Forms of an Activin Receptor-Like Kinase Inhibitor
Application:
17/633,440 →
Publication:
US 2022/0281879
Process for Preparing an Activin Receptor-Like Kinase Inhibitor
Compositions Useful for Treating Disorders Related to Kit
Application:
61/892,086 →
Compositions Useful for Treating Disorders Related to Kit
Application:
61/931,204 →
Compositions Useful for Treating Disorders Related to Kit
Application:
61/975,229 →
Compositions Useful for Treating Disorders Related to Kit
Application:
17/070,556 →
Publication:
US 2021/0284645
Crystalline Forms of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine and Methods of Making
Avapritinib Resistance of Kit Mutants
Application:
17/292,965 →
Publication:
US 2022/0010382
Pyrrolotriazine Derivatives for Treating Kit-and Pdgfra-Mediated Diseases
Treatment of Eosinophilic Disorders with Avapritinib
Application:
17/766,200 →
Publication:
US 2024/0075041
Treatment of Mast Cell Diseases and Eosinophilic Disorders
Application:
17/773,447 →
Publication:
US 2022/0370465
PIK3C2G Fusions
NTRK2 Fusions
PIK3CA Fusions
RAF1 Fusions
Method for Detection of a Tecr:PKN1 or an ANXA4:PKN1 Gene Fusion
Tert Fusions
Prkc Fusions
Prkc Fusions
Fgr Fusions
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
2-(Pyridin-3-Yl)-Pyrimidine Derivatives as Ret Inhibitors
2-(Pyridin-3-Yl)-Pyrimidine Derivatives as Ret Inhibitors
Inhibitors of Ret
Inhibitors of Ret
Inhibitors of Ret
Inhibitors of Ret
Compounds Useful for Treating Disorders Related to Ret
Compounds Useful for Treating Disorders Related to Ret
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Compounds and Compositions Useful for Treating Disorders Related to Ntrk
Compounds and Compositions Useful for Treating Disorders Related to Ntrk
Compositions Useful for Treating Disorders Related to Kit and Pdgfr
Compounds and Compositions Useful for Treating Disorders Related to Ntrk
Compounds and Compositions Useful for Treating Disorders Related to Ntrk
SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES FOR TREATING DISORDERS RELATED TO KIT AND PDGFR
Inhibitors of Activin Receptor-Like Kinase
Inhibitors of Activin Receptor-Like Kinase
Substituted Pyrrolopyridines as Inhibitors of Activin Receptor-Like Kinase
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
MAP4K1 Inhibitors
PCT:
PCT/US2021/013359 ↗
MAP4K1 Inhibitors
PCT:
PCT/US2022/019168 ↗
Egfr Inhibitors
PCT:
PCT/US2022/019597 ↗
Process for Preparing Egfr Inhibitors
PCT:
PCT/US2022/034487 ↗
Pharmaceutical Compositions of an Epidermal Growth Factor Receptor Inhibitor
PCT:
PCT/US2022/034433 ↗
Diazepanone-Fused Pyrimidine Compounds, Compositions and Medicinal Applications Thereof
PCT:
PCT/US2022/022592 ↗
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
PCT:
PCT/US2021/057472 ↗
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
PCT:
PCT/US2021/057474 ↗
Egfr Inhibitors
PCT:
PCT/US2022/034411 ↗
Egfr Inhibitors
PCT:
PCT/US2022/034213 ↗
Egfr Inhibitors
PCT:
PCT/US2022/034214 ↗
Egfr Inhibitors
PCT:
PCT/US2022/034247 ↗
CDK2 Inhibitors
PCT:
PCT/US2022/035122 ↗
CDK2 Inhibitors
PCT:
PCT/US2022/033576 ↗
Pralsetinib Pharmaceutical Compositions
PCT:
PCT/US2021/034811 ↗
Solid Forms of Pralsetinib
PCT:
PCT/US2021/034823 ↗
Method of Preparing Pralsetinib
PCT:
PCT/US2021/061754 ↗
Synthetic Methods and Intermediates for Producing Compounds for Treating Kit- and Pdgfra-Mediated Diseases
PCT:
PCT/US2022/018692 ↗
Salt and Solid Forms of a Kinase Inhibitor
PCT:
PCT/US2022/019776 ↗
Compositions and Methods for Treating Kit-and Pdgfra-Mediated Diseases
PCT:
PCT/US2021/054662 ↗
Inhibitors of Protein Kinase A
PCT:
PCT/US2022/014674 ↗
Salt and Crystal Forms of an Epidermal Growth Factor Receptor Inhibitor
PCT:
PCT/US2022/034550 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 8, 2018
From: STRANSKY, NICOLAS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 045143/0120 →
Assignment of Assignor's Interest
Mar 7, 2019
From: STRANSKY, NICOLAS; WINTER, CHRISTOPHER; HAGEL, MARGIT; HOEFLICH, KLAUS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 048535/0356 →
Assignment of Assignor's Interest
Sep 18, 2019
From: CERAMI, ETHAN G.; LENGAUER, CHRISTOPH; STRANSKY, NICOLAS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 050417/0279 →
Assignment of Assignor's Interest
Jan 7, 2021
From: BROOIJMANS, NATASJA; BRUBAKER, JASON D.; FLEMING, PAUL E.; HODOUS, BRIAN LEWIS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 054843/0337 →
Assignment of Assignor's Interest
May 11, 2021
From: BRUBAKER, JASON D.; MIDUTURU, CHANDRASEKHAR V.; BURKE, MICHAEL J.; DINEEN, THOMAS A.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 056208/0383 →
Assignment of Assignor's Interest
May 12, 2021
From: RAAB, ERICA EVANS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 056218/0464 →
Assignment of Assignor's Interest
May 12, 2021
From: WOLF, BENI B.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 056218/0437 →
Assignment of Assignor's Interest
Sep 14, 2021
From: ROTH, BRUCE; PANDEY, ANJALI; SAXTON, TRACY
To: LENGO THERAPEUTICS, INC.
Reel/Frame 057479/0470 →
Assignment of Assignor's Interest
Sep 14, 2021
From: HALLUR, GURULINGAPPA; MADHYASTHA, NAVEENA; STEPHEN, MICHAEL RAJESH
To: JUBILANT BIOSYS LIMITED
Reel/Frame 057479/0656 →
Assignment of Assignor's Interest
Sep 14, 2021
From: JUBILANT BIOSYS LIMITED
To: LENGO THERAPEUTICS, INC.
Reel/Frame 057479/0950 →
Assignment of Assignor's Interest
Oct 4, 2021
From: STRANSKY, NICHOLAS; KIM, JOSEPH L.
To: BLUEPRINT MEDICINE CORPORATION
Reel/Frame 057688/0923 →
Assignment of Assignor's Interest
Oct 12, 2021
From: JUBILANT THERAPEUTICS INDIA LIMITED
To: LENGO THERAPEUTICS, INC.
Reel/Frame 057770/0714 →
Assignment of Assignor's Interest
Oct 12, 2021
From: RAJAGOPAL, SRIDHARAN; M, NAVEEN SADHU
To: JUBILANT THERAPEUTICS INDIA LIMITED
Reel/Frame 057769/0981 →
Assignment of Assignor's Interest
Oct 12, 2021
From: JUBILANT BIOSYS LIMITED
To: JUBILANT THERAPEUTICS INDIA LIMITED
Reel/Frame 057770/0468 →
Assignment of Assignor's Interest
Nov 2, 2021
From: ROTH, BRUCE; PANDEY, ANJALI; SAXTON, TRACY
To: LENGO THERAPEUTICS, INC.
Reel/Frame 057994/0546 →
Assignment of Assignor's Interest
Nov 2, 2021
From: JUBILANT BIOSYS LIMITED
To: JUBILANT THERAPEUTICS INDIA LIMITED
Reel/Frame 057993/0702 →
Assignment of Assignor's Interest
Nov 2, 2021
From: JUBILANT BIOSYS LIMITED
To: JUBILANT THERAPEUTICS INDIA LIMITED
Reel/Frame 057994/0738 →
Assignment of Assignor's Interest
Nov 2, 2021
From: HALLUR, GURULINGAPPA; MADHYASTHA, NAVEENA; STEPHEN, MICHAEL RAJESH
To: JUBILANT BIOSYS LIMITED
Reel/Frame 057993/0543 →
Assignment of Assignor's Interest
Nov 2, 2021
From: RAJAGOPAL, SRIDHARAN; M., NAVEEN SADHU
To: JUBILANT THERAPEUTICS INDIA LIMITED
Reel/Frame 057993/0638 →
Assignment of Assignor's Interest
Nov 2, 2021
From: ROTH, BRUCE; PANDEY, ANJALI; SAXTON, TRACY
To: LENGO THERAPEUTICS, INC.
Reel/Frame 057993/0436 →
Assignment of Assignor's Interest
Nov 2, 2021
From: JUBILANT THERAPEUTICS INDIA LIMITED
To: LENGO THERAPEUTICS, INC.
Reel/Frame 057993/0801 →
Assignment of Assignor's Interest
Nov 2, 2021
From: HALLUR, GURULINGAPPA; MADHYASTHA, NAVEENA; STEPHEN, MICHAEL RAJESH
To: JUBILANT BIOSYS LIMITED
Reel/Frame 057994/0661 →
Assignment of Assignor's Interest
Nov 9, 2021
From: JUBILANT THERAPEUTICS INDIA LIMITED
To: LENGO THERAPEUTICS, INC.
Reel/Frame 058058/0708 →
Assignment of Assignor's Interest
Jan 13, 2022
From: BRUBAKER, JASON D.; MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 058650/0862 →
Assignment of Assignor's Interest
Jan 13, 2022
From: BRUBAKER, JASON D.; MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 058734/0990 →